CL2018000138A1 - Composicion farmaceutica solida que comprende al compuesto 1 y al compuesto 2 en dispersiones solidas amorfas, y sus perfiles de disolucion. - Google Patents
Composicion farmaceutica solida que comprende al compuesto 1 y al compuesto 2 en dispersiones solidas amorfas, y sus perfiles de disolucion.Info
- Publication number
- CL2018000138A1 CL2018000138A1 CL2018000138A CL2018000138A CL2018000138A1 CL 2018000138 A1 CL2018000138 A1 CL 2018000138A1 CL 2018000138 A CL2018000138 A CL 2018000138A CL 2018000138 A CL2018000138 A CL 2018000138A CL 2018000138 A1 CL2018000138 A1 CL 2018000138A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- solid
- pharmaceutical composition
- dissolution profiles
- solid pharmaceutical
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 229940125904 compound 1 Drugs 0.000 title abstract 3
- 229940125782 compound 2 Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000006185 dispersion Substances 0.000 title 1
- 238000004090 dissolution Methods 0.000 title 1
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 239000008180 pharmaceutical surfactant Substances 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La presente invención presenta composiciones farmacéuticas sólidas que comprenden el Compuesto 1 y el Compuesto 2. En una realización, la composición farmacéutica sólida incluye (1) una primera capa que comprende 100 mg de Compuesto 1, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en dispersión sólida amorfa; y (2) una segunda capa que comprende 40 mg de Compuesto 2, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en una dispersión sólida amorfa.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193639P | 2015-07-17 | 2015-07-17 | |
| US201662295309P | 2016-02-15 | 2016-02-15 | |
| US15/192,211 US20160375087A1 (en) | 2015-06-26 | 2016-06-24 | Solid Pharmaceutical Compositions for Treating HCV |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000138A1 true CL2018000138A1 (es) | 2018-07-13 |
Family
ID=57834557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000138A CL2018000138A1 (es) | 2015-07-17 | 2018-01-17 | Composicion farmaceutica solida que comprende al compuesto 1 y al compuesto 2 en dispersiones solidas amorfas, y sus perfiles de disolucion. |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP4681779A2 (es) |
| JP (2) | JP7133466B2 (es) |
| KR (2) | KR20240108528A (es) |
| CN (1) | CN108024964B (es) |
| AU (1) | AU2016296709C1 (es) |
| BR (1) | BR112018000982A2 (es) |
| CA (1) | CA2992722C (es) |
| CL (1) | CL2018000138A1 (es) |
| CO (1) | CO2018000391A2 (es) |
| CR (1) | CR20180088A (es) |
| DO (1) | DOP2018000024A (es) |
| EA (1) | EA201890334A1 (es) |
| EC (1) | ECSP18008411A (es) |
| HK (1) | HK1255203A1 (es) |
| IL (1) | IL256945B2 (es) |
| MX (1) | MX2018000746A (es) |
| PE (1) | PE20180609A1 (es) |
| PH (1) | PH12018500132A1 (es) |
| RU (1) | RU2018105849A (es) |
| SG (1) | SG10202002900YA (es) |
| WO (1) | WO2017015211A1 (es) |
| ZA (1) | ZA201801082B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| AU2020271791A1 (en) * | 2019-04-08 | 2021-11-04 | Abbvie Inc. | Solid pharmaceutical compositions for treating HCV |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
| DE102004008804A1 (de) | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Mehrschichttablette |
| ES2300188B1 (es) | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) * | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| PL2498758T3 (pl) | 2009-11-13 | 2019-02-28 | Astrazeneca Ab | Formulacje tabletek dwuwarstwowych |
| NZ605440A (en) * | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| NZ608720A (en) * | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| LT2897611T (lt) | 2012-09-18 | 2019-12-10 | Abbvie Inc | Hepatito c gydymo būdai |
| RS60881B1 (sr) * | 2013-03-14 | 2020-11-30 | Abbvie Inc | Kombinacija dva antivirusa za lečenje hepatitisa c |
| CN107920996A (zh) | 2015-06-26 | 2018-04-17 | 艾伯维公司 | 用于治疗hcv的固体药物组合物 |
-
2016
- 2016-07-18 HK HK18114330.0A patent/HK1255203A1/zh unknown
- 2016-07-18 CN CN201680052931.3A patent/CN108024964B/zh not_active Expired - Fee Related
- 2016-07-18 JP JP2018501944A patent/JP7133466B2/ja active Active
- 2016-07-18 CA CA2992722A patent/CA2992722C/en active Active
- 2016-07-18 SG SG10202002900YA patent/SG10202002900YA/en unknown
- 2016-07-18 CR CR20180088A patent/CR20180088A/es unknown
- 2016-07-18 KR KR1020247020998A patent/KR20240108528A/ko active Pending
- 2016-07-18 PE PE2018000084A patent/PE20180609A1/es unknown
- 2016-07-18 EP EP25203069.7A patent/EP4681779A2/en active Pending
- 2016-07-18 RU RU2018105849A patent/RU2018105849A/ru unknown
- 2016-07-18 AU AU2016296709A patent/AU2016296709C1/en active Active
- 2016-07-18 MX MX2018000746A patent/MX2018000746A/es unknown
- 2016-07-18 EP EP16745584.9A patent/EP3324941A1/en active Pending
- 2016-07-18 BR BR112018000982A patent/BR112018000982A2/pt not_active Application Discontinuation
- 2016-07-18 KR KR1020187004422A patent/KR102824158B1/ko active Active
- 2016-07-18 IL IL256945A patent/IL256945B2/en unknown
- 2016-07-18 WO PCT/US2016/042806 patent/WO2017015211A1/en not_active Ceased
- 2016-07-18 EA EA201890334A patent/EA201890334A1/ru unknown
-
2018
- 2018-01-16 PH PH12018500132A patent/PH12018500132A1/en unknown
- 2018-01-16 CO CONC2018/0000391A patent/CO2018000391A2/es unknown
- 2018-01-17 CL CL2018000138A patent/CL2018000138A1/es unknown
- 2018-01-17 DO DO2018000024A patent/DOP2018000024A/es unknown
- 2018-02-06 EC ECIEPI20188411A patent/ECSP18008411A/es unknown
- 2018-02-16 ZA ZA2018/01082A patent/ZA201801082B/en unknown
-
2022
- 2022-07-01 JP JP2022107289A patent/JP7472199B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001993A1 (es) | Inhibidores selectivos de jak1. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| MX2017004906A (es) | Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma. | |
| CL2013001338A1 (es) | Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih. | |
| UY37098A (es) | Moduladores de ror-gamma | |
| UY37205A (es) | Inhibidores de bromodominios | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| TR201821116A2 (tr) | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ | |
| MX387731B (es) | Composiciones farmacéuticas orales de mesalazina. | |
| CL2017001840A1 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para preparar y usar las mismas. | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| EA201991287A1 (ru) | Твердые фармацевтические композиции на основе тикагрелора для перорального применения | |
| ECSP18000689A (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| CL2018000138A1 (es) | Composicion farmaceutica solida que comprende al compuesto 1 y al compuesto 2 en dispersiones solidas amorfas, y sus perfiles de disolucion. | |
| GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
| EP3419669A4 (en) | FORMULATION WITH DOUBLE RELEASE RATE AND HIGH ACTIVE LOAD | |
| CL2016003271A1 (es) | Métodos para tratar infecciones | |
| AR114396A1 (es) | Formulaciones de liberación sostenida de ácido bempedoico | |
| CR20130631A (es) | Composiciones sòlidas | |
| MX2018002449A (es) | Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas. | |
| BR112017017774A2 (pt) | composto, composição farmacêutica e método para fabricar um medicamento | |
| UA116464U (uk) | Протимікробний засіб |